CN100388931C - Medicine for treating pelvic inflammation and its preparing method - Google Patents
Medicine for treating pelvic inflammation and its preparing method Download PDFInfo
- Publication number
- CN100388931C CN100388931C CNB2005100514241A CN200510051424A CN100388931C CN 100388931 C CN100388931 C CN 100388931C CN B2005100514241 A CNB2005100514241 A CN B2005100514241A CN 200510051424 A CN200510051424 A CN 200510051424A CN 100388931 C CN100388931 C CN 100388931C
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- blood
- thick paste
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicine for treating pelvic inflammation and a preparing method thereof. The preparation is prepared by combining medicines of honeysuckle stem, sargentgloryvine, liquorice root, dyers woad leaf, dandelion, red peony root, rhubarb, red sage root, giant knotweed rhizome, szechwan chinaberry fruit and corydalis tuber according to a prescription selected by a famous pharmacologist: professor Zhao Dongke according to traditional Chinese medical theory and practice so as to cause the medicinal effects to generate synergistic effects. The preparation can be orally taken in a traditional Chinese medicine mode so as to rapidly obtain the effects on promoting qi, relieving pain, dredging the circulation of qi and blood, relieving toxin, eliminating dampness, removing dampness for arresting itching, diminishing inflammation, controlling bacteria, disinfecting, sterilizing, nourishing blood, moistening dryness, inducing diuresis for removing edema, promoting the blood circulation for removing blood stasis, softening and resolving hard masses, strengthening and consolidating body resistance, coordinating yin and yang, promoting the circulation of the qi and the blood and enhancing body immune functions. The medicines are processed by the following processes: extracting by ethanol through refluxing, decocting by water to obtain thick paste, drying the thick paste, crushing the dried thick paste into fine powder, granulating, etc. The observation of clinical tests shows that the medicine of the present invention called Fuyanshu has obvious curative effects on pathological symptoms such as abdominal pain, leukorrhagia, etc. caused by acute pelvic inflammation and chronic pelvic inflammation.
Description
Technical field
The invention discloses a kind of medicine for the treatment of the gynaecopathia pelvic inflammatory disease and preparation method thereof, is the preparation of feedstock production with Chinese medicine specifically, belongs to the field of Chinese medicines.
Background technology
Pelvic inflammatory disease comprises acute pelvic inflammatory disease and chronic pelvic inflammatory disease, wherein infect be commonly encountered diseases because of because inflammation is shown effect repeatedly, often can cause simulataneous insufficiency and excessive, QI and blood being ill simultaneously, radical cure is difficulty especially, and so-called simulataneous insufficiency and excessive is meant that the case of a physically strong patient running a high fever of existing irritability stasis, damp and hot friendship resistance has the situation of weakness of the spleen and stomach even QI and blood deficiency again, and the humidogene stasis of blood is given birth in pent-up fire-transformation with the passing of time again, invade channels, Persistent Pain is difficult more, and time ends when doing, and shows as multiple disease type.Clinical manifestation is heating, headache, and inappetence and lower abdominal pain and lumbago, lower abdomen weigh down to expand, and lumbosacral region is ached, and increases the weight of after the fatigue of being everlasting, the sexual intercourse, during defecation and before and after the menstruation.When being arranged, peritonitis can accompany gastrointestinal symptom, as nauseating, stomachache, abdominal distention, diarrhea etc.; Dysuria, frequent micturition, dysurea appear when urethra is got involved; Diarrhoea, constipation can appear when rectal wall is got involved, menstruation and leucorrhoea grow in quantity etc., and the relapse rate height, complication is many, is one group of commonly encountered diseases, the frequently-occurring disease of puzzlement health of people.
At present, the method for treatment pelvic inflammatory disease is a lot, comprises doctor trained in Western medicine and Chinese traditional treatment.Doctor trained in Western medicine is mainly used treatments such as antibiotics to this type of patient, treatment cycle is long, and side effect is big, easily recurrence.Traditional Chinese medical science traditional therapy, anti-inflammatory analgetic by force often, symptomatic treatment in acute condition, relieving the primary symptom in a chronic case, that tests is clinical, though certain curative effect is arranged, imperfection, general relief of symptoms is difficult to tackle the problem at its root.
Summary of the invention
Purpose of the present invention is exactly the problem that exists at above-mentioned prior art, and a kind of cause of disease at the pelvic inflammatory disease morbidity that provides, and Synergistic treatment comprehensively can the human body immunity improving function, again can reducing swelling and alleviating pain, and antiinflammatory bacteriostatic Chinese medicine preparation.
The perineal position QI and blood in length and breadth, meridians are staggered, easily make the damp invasion of lower energizer stagnation of blood stasis.The traditional Chinese medical science is thought primary disease and positive QI-insufficiency, and qi-blood disharmony, space between skin and muscles is solid, and multiple sense poison is evil, and the cohesion skin forms.Human body overstrain Mental fatigue, positive QI-insufficiency, sexual life is unclean, and is then qi-blood disharmony, and the integrated environment of YIN and YANG in a relative equilibrium is upset, and it is evil to meet poison, vital QI cannot conquer pathogen and falling ill then, so-called " institute of heresy gathers, its gas must void ".
This preparation is the pathogeny of famous pharmacologist professor ZhaoDongKe according to pelvic inflammatory disease, according to " interior warp " " hard person disappear it, appearance person remove it, the disease with retention of pathogen in the body should be treated by elimination therapy " the Therapeutic Principle, excavate traditional Chinese medical science abundant materials, in conjunction with clinical experience, carry out that big quantity research draws, each amounts of components all has better curative effect in the following weight parts scope.
Radix Et Rhizoma Rhei 1-3 part, Caulis Lonicerae 8-15 part, Caulis Sargentodoxae 8-15 part, Radix Glycyrrhizae 0.5-1.5 part,
Folium Isatidis 2-4 part, Herba Taraxaci 2-4 part, Radix Paeoniae Rubra 2-4 part, Radix Salviae Miltiorrhizae 2-4 part,
Rhizoma Polygoni Cuspidati 2-4 part, Fructus Toosendan 2-4 part, Rhizoma Corydalis 2-4 part.
Be preferably: 2 parts of Radix Et Rhizoma Rhei, 10 parts of Caulis Loniceraes, 10 parts of Caulis Sargentodoxae, 1 part in Radix Glycyrrhizae,
3 parts of Folium Isatidiss, 3 parts of Herba Taraxacis, 3 parts of Radix Paeoniae Rubra, 3 parts of Radix Salviae Miltiorrhizaes,
3 parts of Rhizoma Polygoni Cuspidati, 3 parts of Fructus Toosendans, 3 parts of Rhizoma Corydalis.
The modern pharmacological research Radix Et Rhizoma Rhei contains anthraquinone derivative, rheotannic acid and related substances gallic acid thereof etc. to be had astringing to arrest diarrhea, heat and toxic materials clearing away, clearing away heat-fire, hemostasis, detoxifcation, blood circulation promoting and blood stasis dispelling, lets out warm merit clearly, clearing away heat-fire, removing pathogenic heat from blood and toxic substance from the body effect are preferably arranged, Radix Et Rhizoma Rhei also has anti-infectious function, and virus is also had inhibitory action.Rhizoma Corydalis contains alkaloids such as Rhizoma Corydalis first element, second element, ugly element, and contain volatile oil, because of the alkaloid of the clear and definite free state of its effective ingredient is insoluble in water, so directly be used as medicine after adopting pulverizing, the one, can guarantee that effective ingredient is not damaged because of heating, the 2nd, directly add in the extractum, can shorten drying time, reduce loss of effective components.Radix Salviae Miltiorrhizae contains TANSHINONES first, TANSHINONES second, TANSHINONES third, pigment vitamin E etc.Radix Paeoniae Rubra contains benzoic acid, paeoniflorin, tannin etc., and its effective ingredient major part of above Chinese medicine is a liposoluble constituent, and water solublity is arranged again, so adopt the alcohol extraction method earlier, medicinal residues and other drug water are together carried, and its effective ingredient is extracted fully as far as possible.Caulis Lonicerae contains lonicerin, this rhinoceros grass element, tannin, tannic acid, alkaloid etc.Caulis Sargentodoxae mainly contains the tannin constituents.Radix Glycyrrhizae contains glycyrrhizin, liquiritin, liquiritigenin, neoliquriitin and glycoside unit mannitol, saccharide organic acid etc.Folium Isatidis contains indigo glycoside and flavones ingredient.Herba Taraxaci contains taraxol, taraxacin, taraxacin, pectin, choline, caffeic acid, inositol etc.Fructus Toosendan contains a river element, alkaloid, Flos Camelliae Japonicae phenol, resin, tannin etc.A river element is anthelmintic effective ingredient, and each effective ingredient of above medicine mostly is the water capacity, so adopt the decocting cooking method.
Above-mentioned all flavor medicine combinations make each efficacy of drugs produce synergism, the cause of disease at the pelvic inflammatory disease morbidity, adopt traditional Chinese medical science interior oral administration, clearing away heat-damp and promoting diuresis, promoting the circulation of QI to relieve pain, the venting QI-blood that relaxes, detoxifcation dampness, removing damp to relieve itching, antiinflammatory are antibacterial, disinfection, blood enriching and dryness moistening, inducing diuresis to remove edema, activating blood circulation to dissipate blood stasis, hard masses softening and resolving, collateral dredging chemical fibre, QI invigorating are given birth to sun, benefit is defended consolidating superficial resistance, consolidated and set upright, regulate negative and positive, promote QI-blood circulation, the human body immunity improving function is got and is imitated the speed victory.
Another object of the present invention provides manufacturing method for above mentioned medicine.
The alkaloid of the clear and definite free state of Rhizoma Corydalis effective ingredient is insoluble in water, so directly be used as medicine after adopting pulverizing, the one, can guarantee that effective ingredient is not damaged because of heating, the 2nd, directly add in the extractum, can shorten drying time, reduce loss of effective components, so be ground into fine powder after getting the clean system of Rhizoma Corydalis earlier.
Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Rhizoma Polygoni Cuspidati effective ingredient major part are liposoluble constituent, and water solublity is arranged again, so adopt the alcohol extraction method earlier, medicinal residues and other drug water are together carried, and its effective ingredient is extracted fully as far as possible.Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Rhizoma Polygoni Cuspidati mixes, add 4-6 and doubly measure 95% alcohol reflux 2 times, merged 2 extracting solution in each backflow 1.5-2.5 hour, filter, filtrate recycling ethanol, ethanol extraction is concentrated into the thick paste that relative density is 1.31-1.41 (60 ℃ of heat is surveyed), medicinal residues and Caulis Lonicerae after the alcohol extraction, Caulis Sargentodoxae, Radix Glycyrrhizae, Folium Isatidis, Herba Taraxaci, Radix Et Rhizoma Rhei, Fructus Toosendan decocts with water 3 times, adds 8-12 times of water gaging for the first time and decocts 1.5-2.5 hour, adding for the second time 6-10 times of water gaging decocted 1-2 hour, add 5-7 times of water gaging for the third time and decocted 0.5-1.5 hour, merge 3 times decoction liquor, filter, filtrate is concentrated into thick paste and the merging of above-mentioned thick paste that relative density is 1.35-1.45 (60 ℃ of heat are surveyed), drying is ground into fine powder, adds the Rhizoma Corydalis fine powder, granulate, drying, granulate is sub-packed in No. 0 capsule and gets final product.
This composition of medicine also can be made tablet, pill, powder, electuary, unguentum, oral liquid.
The present invention is described in further detail below in conjunction with instantiation that the inventor provides.
The specific embodiment
Embodiment 1
Take by weighing each raw material according to following weight parts:
1 part of Radix Et Rhizoma Rhei, 8 parts of Caulis Loniceraes, 8 parts of Caulis Sargentodoxae, 0.5 part in Radix Glycyrrhizae,
2 parts of Folium Isatidiss, 2 parts of Herba Taraxacis, 2 parts of Radix Paeoniae Rubra, 2 parts of Radix Salviae Miltiorrhizaes,
2 parts of Rhizoma Polygoni Cuspidati, 2 parts of Fructus Toosendans, 2 parts of Rhizoma Corydalis.
Manufacture method: be ground into fine powder after getting the clean system of Rhizoma Corydalis earlier, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Rhizoma Polygoni Cuspidati mixes, add 5 times of amount 95% alcohol reflux 2 times, the each backflow merged 2 extracting solution in 2 hours, filtered filtrate recycling ethanol, ethanol extraction is concentrated into the thick paste that relative density is 1.36 (60 ℃ of heat are surveyed), medicinal residues and Caulis Lonicerae after the alcohol extraction, Caulis Sargentodoxae, Radix Glycyrrhizae, Folium Isatidis, Herba Taraxaci, Radix Et Rhizoma Rhei, Fructus Toosendan decocts with water 3 times, adds 10 times of water gagings for the first time and decocts 2 hours, adds 8 times of water gagings for the second time and decocts 1.5 hours, adding 6 times of water gagings for the third time decocted 1 hour, merge 3 times decoction liquor, filter, filtrate is concentrated into thick paste and the merging of above-mentioned thick paste that relative density is 1.36 (60 ℃ of heat are surveyed), dry, be ground into fine powder, add the Rhizoma Corydalis fine powder, granulate, dry, granulate is sub-packed in No. 0 capsule, packages spare after the sterilization.
Usage: every day 3 times, each 5 oral.
Embodiment 2
Take by weighing each component raw material according to following weight parts:
3 parts of Radix Et Rhizoma Rhei, 15 parts of Caulis Loniceraes, 15 parts of Caulis Sargentodoxae, 1.5 parts in Radix Glycyrrhizae,
4 parts of Folium Isatidiss, 4 parts of Herba Taraxacis, 4 parts of Radix Paeoniae Rubra, 4 parts of Radix Salviae Miltiorrhizaes,
4 parts of Rhizoma Polygoni Cuspidati, 4 parts of Fructus Toosendans, 4 parts of Rhizoma Corydalis.
Manufacture method and usage are with embodiment 1.
Embodiment 3
Take by weighing each component raw material according to following weight parts:
2 parts of Radix Et Rhizoma Rhei, 10 parts of Caulis Loniceraes, 10 parts of Caulis Sargentodoxae, 1 part in Radix Glycyrrhizae,
3 parts of Folium Isatidiss, 3 parts of Herba Taraxacis, 3 parts of Radix Paeoniae Rubra, 3 parts of Radix Salviae Miltiorrhizaes,
3 parts of Rhizoma Polygoni Cuspidati, 3 parts of Fructus Toosendans, 3 parts of Rhizoma Corydalis.
Manufacture method and usage are with embodiment 1.
In order to verify the present invention, the inventor has carried out clinical trial, and drug nomenclature of the present invention is " woman is scorching relaxes ".
Clinical experiment report
1. clinical data
1.1 physical data
1.1.1 case source: select outpatient service and pelvic inflammatory disease patient 200 examples of being in hospital, whole cases all meet includes the case choice criteria in.
1.1.2 the age: maximum 48 years old age of test group, minimal ages 22 years old; Maximum 45 years old age of matched group, minimal ages 20 years old, two groups of age comparabilities detect, and see table 1 for details.
Table 1 liang group age distribution situation comparison (year)
X
2(R×C)＝0.2451 P＞0.05
As can be seen from the above table, test group and matched group age distribution there was no significant difference, P＞0.05 has comparability.
1.1.3 occupation: two groups of patient's occupation distribution situation comparabilities detect, and see table 2 for details.
The professional distribution situation of table 2
X
2(R×C)＝0.4780 P＞0.05
As can be seen from the above table, test group and matched group occupation distribution there was no significant difference, P＞0.05 has comparability.
1.1.4 sick the kind: the two groups of sick kind situation of patient comparabilities detect, and see table 3 for details.
The sick distribution situation of planting of table 3 liang group patient
X
2(2×2)＝0.0239 P＞0.05
As can be seen from the above table, the sick distribution there was no significant difference of planting of test group and matched group, P＞0.05 has comparability.
2 cases are selected
2.1 Western medicine diagnose standard
" pelvic inflammatory disease " diagnostic criteria in the reference " the clinical guidance oranon of new Chinese medicine treatment female genital disease ":
2.1.1 acute pelvic inflammatory disease: (1) symptom: heating, headache, inappetence and lower abdominal pain.When being arranged, peritonitis can accompany gastrointestinal symptom, as nauseating, stomachache, abdominal distention, diarrhea etc.; Dysuria, frequent micturition, dysurea appear when urethra is got involved; Diarrhoea, constipation can appear when rectal wall is got involved.(2) general inspection: be face of acute ill, fervescence, heart rate is fast, abdominal distention, lower abdomen has muscle tonus, tenderness, rebound tenderness, hypoactive bowel sounds or disappearance.(3) gynecologial examination: vaginal congest, secretions is many, and arched roof is touched a tender spot and cervix uteri is lifted pain obviously.Body of uterus is bigger, and tenderness is arranged, and both sides, uterus adnexa tenderness is obvious, has fashion can lay one's hand on and enclosed mass.During the other ICT in uterus, can lay one's hand on the lower abdomen one or both sides has lamellar to thicken, and has abscess to exist, and the position is when low, can lay one's hand on and the back arched roof has lump to have fluctuation.
2.1.2 chronic pelvic inflammatory disease: (1) symptom: lower abdomen and lumbago, lower abdomen weigh down to expand, and lumbosacral region is ached, and increase the weight of after the fatigue of being everlasting, the sexual intercourse, during defecation and before and after the menstruation.Can increase and leucorrhoea grow in quantity with low grade fever, menstruation.(2) gynecologial examination: the uterus often is the position, back, and limitation of activity or adhesion are fixed, and can touch streak thing in the one or both sides, uterus during salpingitis, and mild tenderness is arranged; During the inflammation of pelvic cavity connective tissue, the one or both sides, uterus have that lamellar thickens, tenderness; Or lay one's hand on and enclosed mass in the pelvic cavity one or both sides.
2.1.3 standards of grading:
Uterine activity is limited, tenderness 5 minutes
That fallopian tube is is streak, tenderness 5 minutes
The one or both sides, uterus have that lamellar thickens, tenderness 5 minutes
The lower abdomen waist is ached and was dropped 3 fens
Profuse leukorrhea 1 minute
Low grade fever 1 minute
Abdominal pain in menstruation 1 minute
The every increase of the course of disease added 0.5 fen in 1 year
Above iterated integral is a severe 15 fens above persons; 10-14 is divided into moderate; 5-9 is divided into slightly.
2.2 Chinese medical discrimination
2.2.1 symptom of stagnation of blood stasis and toxin: low thermal fluctuation, Mental fatigue flesh is soft, the inferior belly gas pain tenderness, soreness of waist poor appetite, rectal tenesmus, the yellow thick frowziness of leukorrhagia, constipation due to dry stool or not well, yellowish or reddish urine is deficient, red tongue, tongue is how yellow greasy, thready and rapid pulse.
2.2.2 syndrome of qi stagnation and blood stasis: lower abdomen dull pain or distending pain, the waist sacrum is miserable, its sx after menstrual period or fatigue, or profuse leukorrhea, yellow skin or white, body of the tongue is slightly dark, greasy fur on tongue, stringy and thready pulse.
2.2.3 case is included standard in: meet vulvitis, vaginitis, chronic cervicitis, acute and chronic pelvic inflammatory disease diagnosis and Chinese medical discrimination person can include case in.
2.2.4 exclusion standard: (1) age is at under-18s, person more than 60 years old.(2) gestation or women breast-feeding their children.(3) to this medicine composition allergy sufferers.(4) be associated with serious primary disease such as cardiovascular, liver, kidney and blood system, psychotic.(5) be not inconsistent and the Chinese medical discrimination person.(6) all standards of including in that do not meet, medication person in accordance with regulations not can't judge that curative effect or data are not congruent to affect the treatment or safety judgement person.
3 test methods
3.1 case source: the outpatient service of clinical trial unit and inpatient, out-patient's strict control variable factor and drug combination voluntarily are with the comparability of guarantee test.
3.2 blind method is selected and implemented: adopt single blind observation plan, 200 routine cases adopt the completely random method of dividision into groups.
3.3 administrated method: the scorching relieving capsule of test group medicine woman is provided by Yangling Medicine Pharmaceutical Co., Ltd., and every day 3 times, each 5,14 days is a course of treatment; Matched group medicine BAIDAI WAN, every day 2 times, each 2g (watered pill).
4 efficacy determinations
4.1 acute pelvic inflammatory disease
Recovery from illness: General Symptoms disappears, and general inspection and pelvioscopy are normal, and chemical examination is normal.
Produce effects: General Symptoms disappears, and general inspection is normal, and pelvic lump is dwindled, and tenderness alleviates, and chemical examination is normal.
Effectively: General Symptoms takes a turn for the better, and general inspection and pelvioscopy can slightly take a favorable turn, and chemical examination is normal.
Invalid: symptom and sign is with before treating.
4.2 chronic pelvic inflammatory disease
Recovery from illness: symptom, sign and inspection all recover normal, and integration is 0 minute.
Produce effects: transference cure, gynecologial examination has clear improvement, and the treatment back reduces more than 2/3 than the preceding integration of treatment.
Effectively: symptom, sign and check all to have and alleviate, treatment back than treatment before integration reduction more than 1/3.
Invalid: the treatment back does not have improvement.
5 therapeutic outcomes
5.1 two groups of general curative effects are judged contrast, see table 4 for details.
Table 4 liang group general curative effect situation
Ridit analyzes: R
Examination=0.4329, R
Right=0.3258, U=2.079, P＜0.05
As can be seen from the above table, the test group general curative effect obviously is better than matched group, between both curative effects significant difference is arranged, P＜0.05.
5.2 sick kind of test group distributes and the curative effect situation, sees table 5 for details.
The sick kind of table 5 test group distributes and the curative effect situation
Ridit analyzes: R
Examination=0.3709, R
Right=0.3754, U=0.0781, P＞0.05.
As can be seen from the above table, the sick kind of test group distributes and the curative effect no significant difference P＞0.05.
5.3 the relation of test group age and curative effect sees table 6 for details.
The relation of table 6 test group age and curative effect
Ridit analyzes: R
＜300=0.5079, R
30=0.4931, R
50=0.4946 X
2=0.1627, P＞0.05.
As can be seen from the above table, test group age and curative effect there was no significant difference, P＞0.05.
5.4 the relation of test group occupation and curative effect sees table 7 for details.
The relation of occupation of table 7 test group and curative effect
Ridit analyzes: R
The worker=0.508, R
Do=0.497, R
Other=0.463 X
2=3.06, P＞0.05.
As can be seen from the above table, the test group occupation distributes and the curative effect there was no significant difference P＞0.05.
5.5 test group Chinese medical discrimination and curative effect situation see table 8 for details.
Table 8 test group Chinese medical discrimination and curative effect situation
Ridit analyzes: R
Knot in the stasis of blood poison=0.3897, R
Stagnation of QI blood produces the stasis of blood=0.3826, U=0.1514 P＞0.05.
As can be seen from the above table, test group Chinese medical discrimination typing curative effect there was no significant difference, P＞0.05.
5.6 test group and matched group see Table 9 to the efficacy result of clinical symptoms.
Table 9 test group and matched group are observed the clinical symptoms efficacy result
The scorching relieving capsule of last table explanation woman except that lustreless complexion, all is higher than matched group, P＜0.05 to clinical each symptom.Two groups of curative effect difference of lustreless complexion symptom nonsignificance (P＞0.05).
5.7 the scorching relieving capsule of woman is observed the therapeutic outcome of urgent chronic pelvic inflammatory disease, sees Table 10.
The scorching relieving capsule of table 10 woman is to the observation of urgent chronic pelvic inflammatory disease therapeutic outcome
Most of patients recovers normal after two courses of treatment.
5.8 safety analysis
Scorching relieving capsule of test group woman and matched group BAIDAI WAN are not found obvious toxic-side effects and untoward reaction in the experimental observation process, before and after the treatment test group and matched group patient blood, urine, stool routine regulating liver-QI, kidney function test and Electrocardioscopy have all been done, check result is all no abnormal, show and use said preparation safety, and have no side effect.
6 conclusions
6.1. by the clinical comparison test, this reagent has significant curative effect to acute and chronic pelvic inflammatory disease patient as can be seen, its total effective rate is 91.85%.
6.2 said preparation is 92% to the total effective rate of acute pelvic inflammatory disease, the total effective rate of chronic pelvic inflammatory disease is 91.7%, and both analyze there was no significant difference through Ridit.
6.3 said preparation to lower abdomen lumbar and back pain and the menstruation that acute and chronic pelvic inflammatory disease causes increase, the improvement effect of symptom such as leucorrhoea grow in quantity is obvious, after two courses of treatment recovers normal more.
6.4 said preparation is analyzed there was no significant difference to Ridit between the segmentation of acute and chronic pelvic inflammatory disease patient's age, occupation and TCM Syndrome Type and the curative effect, P＞0.05 shows that said preparation is not subjected to the influence of above-mentioned factor, and curative effect is approaching.
6.5 said preparation except that lustreless complexion, all is higher than matched group (P＜0.05) to clinical each symptom.Two groups of curative effect difference of lustreless complexion symptom nonsignificance (P＞0.05).
6.6 in the said preparation clinical trial process, do not find obvious toxic-side effects and untoward reaction, by to blood, urine, stool routine before and after the treatment, the inspection of liver, renal function and electrocardiogram etc. shows that it is safe using said preparation.
By 200 examples (scorching relieving capsule 150 examples of test group woman, matched group BAIDAI WAN 50 examples) clinical trial is observed, and shows the scorching relieving capsule of woman to the caused stomachache of acute and chronic pelvic inflammatory disease, and diseases such as leucorrhoea grow in quantity have significant curative effect, do not find toxic and side effects and untoward reaction, illustrate that said preparation is safe and effective.
Claims (2)
1. preparation method for the treatment of the medicine of pelvic inflammatory disease, make by following bulk drugs: Radix Et Rhizoma Rhei 1-3 part, Caulis Lonicerae 8-15 part, Caulis Sargentodoxae 8-15 part, Radix Glycyrrhizae 0.5-1.5 part, Folium Isatidis 2-4 part, Herba Taraxaci 2-4 part, Radix Paeoniae Rubra 2-4 part, Radix Salviae Miltiorrhizae 2-4 part, Rhizoma Polygoni Cuspidati 2-4 part, Fructus Toosendan 2-4 part, Rhizoma Corydalis 2-4 part, it is characterized in that, follow these steps to preparation:
(A) will be ground into fine powder after the clean system of Rhizoma Corydalis;
(B) Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Rhizoma Polygoni Cuspidati mix, and add 4-6 and doubly measure 95% alcohol reflux 2 times, and reflux merged 2 extracting solution in 1.5-2.5 hour at every turn, filtered filtrate recycling ethanol;
(C) ethanol extraction is concentrated into the thick paste that relative density is 1.31-1.41;
(D) medicinal residues and Caulis Lonicerae, Caulis Sargentodoxae, Radix Glycyrrhizae, Folium Isatidis, Herba Taraxaci, Radix Et Rhizoma Rhei, Fructus Toosendan decoct with water 3 times after the alcohol extraction, adding for the first time 8-12 times of water gaging decocted 1.5-2.5 hour, adding for the second time 6-10 times of water gaging decocted 1-2 hour, adding 5-7 times of water gaging for the third time decocted 0.5-1.5 hour, merge 3 times decoction liquor, filter;
(E) filtrate is concentrated into thick paste and thick paste merging last time that relative density is 1.35-1.45, and drying is ground into fine powder;
(F), granulate with Rhizoma Corydalis fine powder mix homogeneously.
2. preparation method as claimed in claim 1 is characterized in that described medicine is made tablet, pill, powder, electuary, unguentum, capsule or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100514241A CN100388931C (en) | 2005-03-04 | 2005-03-04 | Medicine for treating pelvic inflammation and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100514241A CN100388931C (en) | 2005-03-04 | 2005-03-04 | Medicine for treating pelvic inflammation and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1682915A CN1682915A (en) | 2005-10-19 |
| CN100388931C true CN100388931C (en) | 2008-05-21 |
Family
ID=35262534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100514241A Expired - Fee Related CN100388931C (en) | 2005-03-04 | 2005-03-04 | Medicine for treating pelvic inflammation and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100388931C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100431581C (en) | 2006-01-20 | 2008-11-12 | 丽珠医药集团股份有限公司 | Traditional Chinese medicine composition for treating fowl influenza, its preparation method and uses |
| CN100453099C (en) * | 2006-04-07 | 2009-01-21 | 重庆希尔安药业有限公司 | Lefukang preparation and its preparing process |
| CN101301414B (en) * | 2008-06-06 | 2010-12-15 | 张宗保 | Chinese medicine for treating pelvic inflammation and preparation |
-
2005
- 2005-03-04 CN CNB2005100514241A patent/CN100388931C/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 国家药品监督管理局国家中成药标准汇编, 中成药地方标准上升国家标准部分，外科 妇科 分册. 第303－304页，国家药品监督管理局. 2002 |
| 国家药品监督管理局国家中成药标准汇编, 中成药地方标准上升国家标准部分，外科 妇科 分册. 第303－304页，国家药品监督管理局. 2002 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1682915A (en) | 2005-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872418B (en) | Medicine for treating pelvic inflammation | |
| CN101816742A (en) | Chinese medicinal composition for treating hemorrhoids and preparation method thereof | |
| CN102940721B (en) | Medicine for treating chronic pelvic inflammation | |
| CN101961479A (en) | Chinese medicinal composition for treating bellyache and preparation method thereof | |
| CN102228603B (en) | Chinese medicine for treating retention of urine | |
| CN105250723A (en) | Medicine for treating diabetes | |
| CN102133271B (en) | Medicinal tea for curing gout | |
| CN102727736A (en) | Constipation treating medicine | |
| CN102727779B (en) | Pharmaceutical composition for treating ovarian cysts and preparation method thereof | |
| CN102600426B (en) | Chinese medicinal preparation for promoting blood circulation to remove blood stasis and preparation method thereof | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN103520669B (en) | The Chinese medicine for the treatment of phlegm-damp accumulation symptom pattern of syndrome obstruction of qi in the chest and cardialgia | |
| CN100388931C (en) | Medicine for treating pelvic inflammation and its preparing method | |
| CN104784511A (en) | Medicine for treating coronary heart disease | |
| CN104225166A (en) | Chinese medicine composition for treating amenorrhea and preparation method thereof | |
| CN103055284A (en) | Traditional Chinese medicine for treating ulcerative colitis and preparation method thereof | |
| CN103520571B (en) | Traditional Chinese medicine for treating qi stagnation and blood stasis syndrome type abdominal mass diseases | |
| CN105031331A (en) | Navel patch for treating dysmenorrhoea and preparation method thereof | |
| CN103520697A (en) | Traditional Chinese medicine for treating qi-yin deficiency syndrome type chest stuffiness and pains | |
| CN103520352B (en) | The Chinese medicine for the treatment of stasis blocking venation pattern of syndrome obstruction of qi in the chest and cardialgia | |
| CN102600424A (en) | Chinese herba preparation for treating nephropyelitis and preparation method of Chinese herba preparation | |
| CN101991751A (en) | Medicament for treating tumors | |
| CN105106674A (en) | Traditional Chinese medicine composition for treating senile skin pruritus and preparation method of composition | |
| CN105435210A (en) | Traditional Chinese medicine oriented permeable drug treatment liquid for treating cold-dampness stasis type lumbar disc herniation and preparation method thereof | |
| CN101850101B (en) | Chinese medicinal composition for treating metrostaxis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YANGLING DONGKE MAIDISEN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHAO DONGKE Effective date: 20100617 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 712100 NO.8, XINQIAO ROAD, YANGLING DEMONSTRATION ZONE, SHANXI PROVINCE TO:710043 4/F, DONGXINGKEJI BUILDING, XINCHENG SCI-TECH INDUSTRY PARK, NO.1, XINKE ROAD, XI AN CITY, SHANXI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100617 Address after: 710043 4 floor, Dongxing science and technology building, Xincheng science and Technology Industrial Park, No. 1, Xinke Road, Shaanxi, Xi'an Patentee after: Dongke Maidisen Pharmaceutical Co., Ltd., Yangling Address before: 712100 No. 8 Xinqiao Road, Yangling demonstration area, Shaanxi Patentee before: Zhao Dongke |
|
| C35 | Partial or whole invalidation of patent or utility model | ||
| IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20090831 Decision number of declaring invalidation: 13754 Granted publication date: 20080521 |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080521 Termination date: 20120304 |